Company Description
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management.
The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development.
It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa.
It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases.
The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989.
The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Country | Denmark |
| Founded | 1923 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 66,700 |
| CEO | Maziar Doustdar |
Contact Details
Address: Novo Alle 1 Bagsvaerd, 2880 Denmark | |
| Phone | 45 44 44 88 88 |
| Website | novonordisk.com |
Stock Details
| Ticker Symbol | NVO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| CIK Code | 0000353278 |
| CUSIP Number | 670100205 |
| ISIN Number | US6701002056 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Maziar Mike Doustdar B.A. | President, Chief Executive Officer and Member of the Management Board |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer and Member of the Management Board |
| Dr. Martin Holst Lange | Executive Vice President of Research & Development, Chief Scientific Officer and Member of the Management Board |
| Tania Sabroe | Executive Vice President of People, Organisation and Corporate Affairs and Member of Management Board |
| Thilde Hummel Bogebjerg | Executive Vice President of Enterprise IT and Quality and Member of Management Board |
| Michael Novod | Senior Vice President and Head of Investor Relations |
| Robin Evers | Senior Vice President of Medical Affairs, Regulatory and Safety |
| Xia-Ping Zhou | Senior Vice President and President of China |
| Frederik Kier | Senior Vice President of Global Obesity Unit |
| Mads Frederik Rasmussen | Senior Vice President and Head of Clinical Drug Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 5, 2026 | 6-K | Report of foreign issuer |
| Nov 4, 2026 | 6-K | Report of foreign issuer |
| Nov 3, 2026 | 6-K | Report of foreign issuer |
| Oct 26, 2026 | 6-K | Report of foreign issuer |
| Oct 19, 2026 | 6-K | Report of foreign issuer |
| Oct 13, 2026 | 6-K | Report of foreign issuer |
| Oct 6, 2026 | 6-K | Report of foreign issuer |
| Oct 5, 2026 | 6-K | Report of foreign issuer |
| Sep 28, 2026 | 6-K | Report of foreign issuer |
| Sep 21, 2026 | 6-K | Report of foreign issuer |